Enhancer of zeste homolog 2 (EZH2) in endocrine tumors: current knowledge and future directions
- 4 March 2025
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 29 (3) , 159-169
Abstract
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that orchestrates gene expression via epigenetic and non-epigenetic mechanisms. EZH2 performs epigenetic functions by methylating histones and/or non-histone proteins and suppressing or activating target genes. Moreover, non-epigenetic functions involve dysregulation of target genes independent of histone methylation, thereby impacting multiple signaling pathways. EZH2 has emerged as a pivotal player in the initiation of various cancers. EZH2 overexpression facilitated by H3K27me3 is the principal driver. However, the consequent dysregulation of target genes resulting from EZH2 overexpression has emerged as a secondary instigator of tumorigenesis, leading to metastasis and poor prognosis. Further complexity arises from somatic mutations in EZH2 and downstream target genes such as BRAF and RASSF1A. However, understanding its effects on endocrine tumors/cancers remains an underexplored with the potential to significantly enhance clinical outcomes and contribute to human health. Therefore, the present review focuses on the multifaceted functions of EZH2 and its pathophysiological mechanisms in tumor proliferation, with a specific emphasis on endocrine tumors. Investigating EZH2 mechanisms and targeting with inhibitors and drugs is an active area of research that could offer a promising avenue for treatment and a better understanding of molecular therapeutic interventions.Keywords
Funding Information
- University Grants Commission
This publication has 76 references indexed in Scilit:
- Targeting EZH2 for cancer therapy: From current progress to novel strategiesEuropean Journal of Medicinal Chemistry, 2022
- Comparison of Profile of Primary Hyperparathyroidism With and Without Type 2 Diabetes Mellitus: Retrospective Analysis From the Indian Primary Hyperparathyroidism RegistryEndocrine Practice, 2022
- Analyzing Genetic Differences Between Sporadic Primary and Secondary/Tertiary Hyperparathyroidism by Targeted Next-Generation Panel SequencingEndocrine Pathology, 2021
- Morphologic and molecular classification of lung neuroendocrine neoplasmsVirchows Archiv, 2021
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomasHuman Pathology, 2017
- Naturally occurring anti-cancer agents targeting EZH2Cancer Letters, 2017
- Primary hyperparathyroidism: insights from the Indian PHPT registryJournal of Bone and Mineral Metabolism, 2017
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasJournal of Medicinal Chemistry, 2016
- Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancerCancer, 2011